GTG settles another DNA patent suit
In a one-two punch, Genetic Technologies (ASX:GTG) has signed yet another settlement agreement in its legal bid to force US gene screening companies to license its non-coding DNA patents.
The company revealed it has executed a settlement agreement with the Virginia-based Genetics & IVF Institute. GTG filed a lawsuit against the company in late 2012.
The announcement came one day after GTG revealed it had signed a settlement and licensing agreement with Wisconsin’s PreventionGenetics - another company it had sued in late 2012.
These lawsuits were the latest in a line of legal efforts to push companies to take out a licence to GTG’s non-coding DNA patents.
GTG’s patent portfolio covers genetic markers used in the company’s BREVAGen breast cancer risk assessment screening process.
Genetic Technologies shares were trading 2.56% lower at $0.076 as of around 2.30 pm on Tuesday.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
